findmyKOL
Clinical trialNCT04390503TerminatedPhase 2Interventional

Convalescent Plasma for Early Treatment of COVID-19

SponsorAndrew EisenbergerEnrollment223COVID-19SARS-CoV 2
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil
  • National Institute of Infectious Diseases Evandro Chagas (ini)

    Rio de Janeiro, Brazil

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Mar 2021
Primary completion
6 Jan 2022
Completion
6 Jan 2022
Last update posted
28 Aug 2024
Registered enrollment
223
Registry id
NCT04390503

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.